CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Kupando doses first patient in phase 1 trial

Phase 1KUP101Positive
AI Analysis

Summary

Kupando has dosed the first patient in a Phase 1 trial of KUP101 for advanced solid tumours, marking the drug's entry into clinical development.

Clinical Trial Data

Phase

1

Importance:5/10
Sentiment:
0.30
clinical developmentoncologyfirst-in-human
Related Companies

Read the original article

Published by PharmaTimes on August 13, 2026 9:55 AM

Read Original